What Changed
MOFCOM published a new policy package on July 4, 2026, expanding incentives for foreign investment in China’s science and technology sector. The package, codenamed “Sci-Tech Investment Facilitation 2026,” targets foreign R&D centers, technology joint ventures, and venture capital participation in early-stage Chinese tech companies.
The measures include simplified approval procedures for foreign-invested R&D centers, expanded eligibility for national-level R&D tax incentives, and — for the first time — explicit pathways for foreign venture capital firms to invest in technology SMEs designated under China’s “Specialized and New” program.
Why It Matters
Foreign tech investment in China has been under pressure since the 2023 Technology Security Review rules and the tightening of outbound investment screening by the U.S. and EU. China’s high-tech FDI inflows dropped 14% in 2025, according to MOFCOM data cited in Caixin Global. This package signals Beijing’s intent to reverse that trend — without compromising the Technology Security Review framework itself.
The timing is strategic. China’s 14th Five-Year Plan calls for R&D spending to reach 3.5% of GDP by 2027, up from 2.6% in 2025. Foreign-invested R&D centers account for roughly 18% of China’s total corporate R&D expenditure, according to NDRC figures. Attracting more foreign R&D dollars supports the plan’s science self-reliance agenda without relying exclusively on domestic sources.
For foreign firms, the question is not whether China wants your tech investment — it’s whether the terms of access have improved enough to outweigh the geopolitical risk premium. This package suggests the answer is tilting back toward “yes” for certain segments.
What the Package Includes
R&D center expansion. Foreign companies establishing or expanding R&D centers in China can now use a “commitment-based approval” pathway, reducing the approval timeline from 90 to 30 working days. Eligible centers must meet a minimum annual R&D investment threshold of RMB 10 million (about $1.38 million) and employ at least 20 full-time researchers.
Tax incentive access. Foreign-invested R&D centers are now explicitly eligible for the Super Deduction for R&D expenses — a 100% additional deduction on qualifying R&D costs against taxable income. Previously, this benefit was inconsistently applied to foreign entities depending on local tax bureau interpretation. The new policy clarifies nationwide applicability.
VC pathways to tech SMEs. Qualified foreign venture capital firms can now invest in “Specialized and New” SMEs without prior MOFCOM approval for investments under RMB 50 million ($6.9 million). Investments above that threshold still require security review. This opens a segment previously closed to foreign capital: China’s 14,000+ “little giant” enterprises — small but highly specialized tech firms that are national champions-in-waiting.
Government procurement access. The package directs provincial governments to include foreign-invested R&D centers in public procurement of innovation — a market worth an estimated RMB 800 billion ($110 billion) annually. The implementation details vary by province, but Shanghai, Jiangsu, and Guangdong have already published their local guidelines.
What Hasn’t Changed
The Technology Security Review remains in place. Any foreign investment involving “core national technology” — broadly defined to cover AI chips, quantum computing, biotech, and aerospace — still requires case-by-case review with no published timeline. The new package explicitly carves out these sectors.
Data cross-border transfer rules under the 2024 Data Security Regulations also remain unchanged. R&D centers can only export data under approved “general data lists” or through a security assessment for important data. The Shanghai Lingang pilot program, launched in June 2026, provides a template but is not yet national policy.
What You Should Do
- Review your R&D footprint. If your company operates or plans an R&D center in China, the commitment-based approval pathway cuts timeline from 3 months to 30 days. File under the new process at your local MOFCOM office or through the online portal at mofcom.gov.cn.
- Audit your R&D spend. The Super Deduction applies retroactively to the 2025 tax year for foreign-invested R&D centers that meet the criteria. If your China R&D subsidiary spent RMB 10 million+ in 2025, the deduction could save RMB 2.5 million in CIT at the standard 25% rate.
- Evaluate VC opportunities. If you’re a foreign VC or corporate venture arm, the RMB 50 million threshold for MOFCOM-free investment opens access to China’s “little giant” pipeline. Target companies in commercial AI applications (where security review exemptions are likeliest), advanced materials, and medical devices.
One Data Point
The number to remember: 14,000. That’s how many “Specialized and New” little giant enterprises China has designated — and until July 2026, foreign VC firms had no clear legal pathway to invest in them without case-by-case MOFCOM approval. The new RMB 50 million threshold changes that calculus for more than half of these firms.
— China Gateway 360 —
Remote China market entry support, built around execution.
Management and Implementation Framework
Work on china sci-tech investment incentives for foreign companies should begin with a documented business objective, not a form or provider quotation. The team should identify the China activity, responsible entity, location, expected start date, transaction or employee population and internal risk tolerance. These facts determine which approvals, records and controls are proportionate.
Sequence the implementation
A practical sequence moves from fact confirmation to option selection, document preparation, authority or counterparty review, implementation and post-launch verification. Dependencies should be visible. No team should assume that registration, a signed contract or a successful system submission proves operational readiness; bank, tax, HR, finance and local operating steps often have separate completion evidence.
Control ownership and evidence
Implementation quality is visible in the evidence trail left behind. For china sci-tech investment incentives for foreign companies, the accountable group normally includes the investment lead, finance controller, project owner and local-government liaison. Responsibility should be divided between preparation, approval and independent checking. The core file should contain eligibility rules, official notices, application materials, project commitments, approval evidence, payment records and ongoing compliance conditions. Evidence should be dated, attributable to a named owner and linked to the decision or filing it supports. Verbal confirmation is not a substitute for a retained authority notice, counterparty response or approved internal record.
The control calendar should reflect the project screening, application, approval, milestone verification and post-award compliance review. Dependencies and cut-off dates need to be visible to every function that supplies data. Any external provider should receive a written scope, required inputs, response timetable and escalation route. The company remains responsible for reviewing outputs even when execution is outsourced. Known failure modes include assuming eligibility without confirmation, unsupported economic commitments, missed application windows and failure to maintain award conditions; each should have a preventive check and a named reviewer.
Management review and escalation
Progress reporting should distinguish submitted, accepted, activated and independently verified. The status pack should show the decision required, facts confirmed, assumptions still open, monetary or operational exposure, next deadline and responsible owner. Items that depend on local discretion should be labelled clearly. Escalation should occur when an authority rejects a filing, a counterparty requests materially different evidence, a cost or timing threshold is exceeded, or actual operations no longer match the approved setup.
Before go-live, the responsible executive should confirm that legal form, contracts, system configuration, payment authority and record retention are aligned. A short post-implementation review after the first operating cycle should compare planned and actual time, cost and exceptions. That review is where recurring controls are corrected and where lessons become part of the company standard rather than remaining with an individual adviser.
Practical completion checklist
- State the business decision, scope, city, entity and target date.
- Confirm the current official rule and any local implementation requirement.
- Assign preparation, approval and independent review to named owners.
- Retain the documents, calculations and correspondence supporting the decision.
- Test cost, timing and operational assumptions against a downside case.
- Record unresolved issues and the threshold for management escalation.
- Verify the first completed operating cycle and update the control calendar.
Execution Record and Handover
The final record for china sci-tech investment incentives for foreign companies should allow another manager to understand what was decided, which evidence was relied on and which obligations remain open. The handover pack should identify the current operating assumption, the approving executive, the external authority or counterparty involved, the effective date and the next mandatory review. It should also explain any local interpretation, exception or temporary workaround so that it is not mistaken for a permanent rule.
For government support, continuity depends on preserving eligibility rules, official notices, application materials, project commitments, approval evidence, payment records and ongoing compliance conditions. Files should use a consistent naming convention and access should follow the company’s authority matrix. Critical dates belong in a controlled calendar rather than an individual’s inbox. Where a provider holds original submissions or account credentials, the contract and exit plan should guarantee prompt return of records in a usable format.
A quarterly control check should sample one completed transaction or employee cycle, reconcile it to the approved process and record exceptions. Material deviations should be assigned to an owner with a due date; repeated deviations should trigger a process redesign rather than another informal reminder. This creates a defensible link between policy, daily execution and management oversight while keeping the control proportionate to the actual China operation.
